Current status of the hormone therapy during the menopausal transition ans post-menopausa

Authors

  • Pedro R Figueroa Casas

DOI:

https://doi.org/10.31053/1853.0605.v62.n2.27899

Keywords:

.

Abstract

Starting from prospectivc clinical stuclics that have evaluated its benefits and risks, hormotie replacement therapy in rnenopause wornen has been reassessecl in its indications  in the last four years. In October, 2004 a Latinarnerican Experts Consensus was carried out,  such report with sorne modifications is presented in this publication. The conclusions the  experts reached were the foliowing: 1) Hormone Therapy is the goid standard for the  control of moderate to severe vasomotor symptorns; 2) this therapy mut be inclicated in an individual manner and only in syrnptomatic women in which the henefit is greater than the  risk; 3) the Ieast effective dose rnust be used; 4) it rnust he used neither for cardiovascular  prevention, osteoporosis, colon cancer nor for mental disorder; 5) the patient must be  informed about the benefits and risks.

 

Downloads

Download data is not yet available.

References

Rossouw JE, Anderson GL, Prentice RL et al. Risk and henefits of estrogen plus progestin in healthy postmenopausal women: principal results from Women's Health Initiative randoniized controlleci trial. JAMA 2002; 288:321-33.

WHI in the News, Internet, Marzo 2004.

Delgado E. Comunicación Personal, Octubre 2004.

Hersch AL, Stefanick ML, Stafford RS. National use of postmenpausal hormone therapy. JAMA 2004;29 1:47-53.

Manson JE, 1-Isla 3, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl 3 Mcd 2003; 349: 523-34.

Chlebowski RT, Hcndrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in hc-althy postmenopausal women. The Wornen's Health Initiative Randomized Trial. JAMA 2003, 289: 3243-53.

The Women's Health Initiative Steering Comniittee. Effects of conj ugated equine estrogen in postmenopausal women with hysterectomy: The women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.

Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. N Engi J Mcd 2003;348:1839.54.

Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of estrogen plus progestin on the incidence of diabetes in postrnenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004:47:1175-87.

Cusman M, Kulier LH, Prentice R, Estrogen plus progestin and risk of venous thrombosis. JAMA 2004:292: 1573- 80.

Naftolin E Taylor liS, 1-laras R. et al. The Women's Health Initiative could not have Cletected carciloprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-501.

Fernandes CE, Soares-Pereira A, Bonassi-Machado R et al. Consenso da SOBRAC- Associacao Brasileira de Climatério. Terapeutica Hormonal tia pero e na pós-menopausa. Cal). 7 Ed. Medcomm, 2004. Sao Paulo, Brazil.

Basavilvazo MA, Bravo-Rociriguez LM, Carranza-Lira S et al. Primer Consenso Nacional Multidisciplinario sobre Trepia de Reemplazo Hormonal. Rey del Clim 2004; 7 (40): 156-179.

Campodónico 1, Siseles N, Gutierrez E Belardo A et al. Consenso Latinoamericano sobre Terapia Hormonal Pos tm eno pa u sic a. (Memoria Mecanógrama). Salta, Argentina 14-15 de agosto de 2003.
Guidelines for the horrnone treatrnent of women in the menopausal transition and beyond. Position Statement by the Executive Comniittee of the International Menopause So ele ty. Climacteric 2004:7:8-11.

North American Menopause Socicty. Estrogcns and Progestogen use in peri and postmcnopausal women. September 2003 Position Statement of the North American Menopause Society. Menopause 2003; 10:497- 506.

Mattson LA, SkoubySO, Hcikkincn J, Vqheri R, et al. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few sideeffects: randomized comparison with a conventional-close regimen. Climacteric 2004;7:59-69.

Borgfelclt C, Li C. Samsoie G. Lowclose oral combination of 1 7-beta-estracliol a n ci no e t h i st ero n e a ceta te in postrnenopausal women decreases factor VII, fibninogen, antithrombin and plasminogen activator inhibitor- 1 Climacteric 2004:7:78-85.

Prestwood KM, Kenny AM, Kleppinger A, et al. Ultralow-dosc micronized 17-beta estradiol and bone density and bone metabolism in older women. A randomized controlled trial. JAMA 2003:290:1042-48.

Ettinger E, Ensrud E, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density. A randomized clinical trial. Obstct Gynecol 2004: 104:443-51.

Grupo Redactor. Declaración de posición. Posición latinoamericana sobre el estado actual de la terapia hormonal. Internet. Noviembre 11, 2004.

Bossemeyer R. Los consensos latinoamericanos. Presentado en el IV Congreso Latinoamericano de Menopausia. Santiago, Chile, Octubre 31- Noviembre 3,2004

Downloads

Published

2021-03-25

How to Cite

1.
Figueroa Casas PR. Current status of the hormone therapy during the menopausal transition ans post-menopausa. Rev Fac Cien Med Univ Nac Cordoba [Internet]. 2021 Mar. 25 [cited 2024 Jul. 17];62(2):32-6. Available from: https://revistas.unc.edu.ar/index.php/med/article/view/27899

Issue

Vol. 62 No. 2 (2005)

Section

Original Papers

License

Copyright (c) 2020 Universidad Nacional de Córdoba

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).